Inhibrx Biosciences (INBX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Inhibrx Biosciences (INBX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Inhibrx Biosciences's market cap?
Inhibrx Biosciences (INBX) has a market capitalization of approximately
How profitable is Inhibrx Biosciences?
Inhibrx Biosciences runs a net profit margin of -10014.2%, a gross margin of -80.4%, and an operating margin of -9465.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Inhibrx Biosciences generate?
Inhibrx Biosciences reported revenue of
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Inhibrx Biosciences financially healthy?
Inhibrx Biosciences carries a debt-to-equity ratio of -0.28x and a current ratio of 6.46x, with a market beta of 3.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Inhibrx Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Inhibrx Biosciences (INBX) the key facts are: market cap
Track Inhibrx Biosciences's full fundamentals live
Get Inhibrx Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.